返回 Agenda
Hype Versus Reality: Artificial Intelligence and Drug Development
Session Chair(s)
Ranjini Prithviraj, PHD, PMP
Director, Global Medical Affairs, Publication Management
Regeneron, United States
This session will discuss maturation of the development of artificial intelligence (AI) over time and how AI has matured more for R&D and signal detection and less so for regulatory support.
Learning Objective : Discuss how artificial intelligence has matured over time.
Speaker(s)
Results of DIA (Tufts) Survey of 1000+ Members About Their Ideas About Digital Health
Mary Jo Lamberti, PHD, MA
Tufts Center for the Study of Drug Development, United States
Director of Sponsored Research, Research Associate Professor
Artificial Intelligence in Regulatory Affairs
Patrick Brady, PHARMD
IQVIA, United States
Global Head, Therapeutic Innovation & Regulatory Science
What is Believed Can Be Done Versus What is Now Being Done
David Meyers
Microsoft, United States
National Director Life Sciences, US Health and Life Sciences